Retinal Physician

Could DME be treated every 6 months? 👁️ Veeral S. Sheth, MD discusses the COMO & CAPRI phase 3 trials evaluating Duravyu and its potential to reduce treatment burden 👇 🔗 ow.ly/WGUK50Yy4F4 #Ophthalmology #Retina

👁️ Retinal disease burden is high and uneven New meta-analysis shows millions affected by AMD, DR, DME, and RVO, with major disparities by race, geography, and access to care 👇 🔗 Read more: ow.ly/uP1A50Yy8Ab #Retina

🎥 From the Macula Society meeting Dilsher S. Dhoot, MD discusses 5-year data from the GALE extension study, showing durable tissue preservation with pegcetacoplan in geographic atrophy. ▶️ Watch the video: ow.ly/MPeS50YrnWN #Retina #AMD #GeographicAtrophy #Ophthalmology

💉 Anti-VEGF therapy transformed retinal care, but injection burden remains high. Here, Simrat K. Sodhi, MSc, and David S. Boyer, MD review the evolving TKI pipeline and its potential to improve durability in retinal vascular disease. 👉 Read: ow.ly/AnaX50Yp7R2 #Retina

Can photobiomodulation regulate dry AMD? Here, Tiago Rassi, Daniel Berinstein, & Michael Colucciello, examine the evidence behind PBM following FDA authorization of the Valeda system and debate whether the benefits reflect true treatment effects. ow.ly/BTzC50Yp5nQ

🎥 Could optogenetic therapy help restore vision in advanced RP? Christine Nichols Kay, MD shares 3-year results from the MCO-010 trial, showing durable improvements in visual acuity for patients with severe vision loss. ▶️ Watch the video: ow.ly/6yse50Yrn5Y #Retina

🧬 Could dual-pathway gene therapy transform geographic atrophy treatment? Thomas A. Ciulla, MD, MBA explores a strategy combining neuroprotection and complement modulation to address multiple GA disease mechanisms. 👉 Read: ow.ly/aVSw50Yp5Po #Retina #AMD #Ophthalmology

🔍 Is it neovascular AMD… or polypoidal choroidal vasculopathy? Recognizing the difference matters for treatment strategy. New article reviews key diagnostic clues, OCT features, and evidence from trials like EVEREST II and PLANET. 👉 Read more ow.ly/7yzH50Yp2M3 #Retina

📖 The March–April issue of Retinal Physician is now live! This issue focuses on age-related macular degeneration and the evolving retina therapy pipeline. 👉 Read the digital issue: ow.ly/EreN50Yp2Tb #Retina #Ophthalmology #AMD #RetinalDisease #RetinalPhysician

Axpaxli outperformed aflibercept in the phase 3 SOL-1 trial - marking the first successful superiority study against an anti-VEGF in wet AMD. Here, Pravin U. Dugel, MD, discusses the data, regulatory strategy, and what this could mean for nAMD care. 🔗 ow.ly/jo3v50Yn0cP

Do GA trials truly show no visual function benefit, or are current endpoints missing the signal? Zhichao Wu, PhD, and Robyn Guymer, PhD, examine why standard measures may underestimate treatment effects in geographic atrophy. Read more: ow.ly/BWeM50Y811F #RetinaResearch

What if carrying a gene linked to inherited retinal disease does not always lead to disease? Real-world genomic data challenge assumptions about IRD penetrance and raise new questions for genetic testing. Read more: ow.ly/pj2W50Y80Lp #RetinalDisease #Ophthalmology

Which KPIs really matter for retina practices in 2026? Elizabeth Cifers, MBA, MSW, CHC, CPC breaks down the metrics that reveal revenue risk, compliance gaps, and workflow issues early in the year. Read more: ow.ly/fmRS50Y80yI #RetinaPractice #Ophthalmology

Ocular Therapeutix’s investigational intravitreal insert, #Axpaxli (OTX-TKI), demonstrated superior visual maintenance and fluid control in treatment-naïve patients in the phase 3 SOL-1 trial. Read more: ow.ly/oGRp50YhbL5

Do GA trials show no visual function benefit, or are we just measuring the wrong thing? Zhichao Wu & Robyn Guymer discuss why VA and reading speed may miss meaningful change, and how defect-mapping microperimetry could better detect functional impact. 👉 ow.ly/S5pY50YcQTZ

New anatomically specific grading scales aim to standardize ocular toxicity assessment for antibody-drug conjugates and guide dose modification in oncology trials. But real-world adoption remains mixed. Read more: ow.ly/KQIl50Y80B7 #Ophthalmology #Oncology #ClinicalTrials

Why might a stem cell derived RPE implant change the future of geographic atrophy treatment? Sun Young Lee, retina specialist & principal investigator at @USCEye, discusses the PATCH AMD phase 2b trial now recruiting GA patients. Watch: ow.ly/S4Jy50Y80rY #GeographicAtrophy

Modern imaging is transforming care for inherited retinal disorders 👁️🔍 Luke Oh, MD, and Jesse D. Sengillo, MD, explain how multimodal tools enhance diagnosis, monitoring, and treatment. Read more: ow.ly/N78L50XRRk2 #RetinalPhysician #RetinaSurgery

Highlights from Atlantic Coast Retina Club and Macula 2026 capture emerging therapies, surgical insights, and complex case discussions from leaders across retina. Read them here: ow.ly/bGX550Y8172 #RetinaConference #Macula2026

Could wearable technology transform retinal care? 👁️⌚ Raj Kundu and Sharon Fekrat, MD, FASRS, explore how personal health monitors may help clinicians track key ocular and systemic markers of retinal health in real time. 👉 Read more: ow.ly/AgUW50XR9Qw #Retina